PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.
PD-1
TIGIT
Th1 immunity
immunosuppression
nivolumab and ipilimumab
oesophageal adenocarcinoma
perioperative
surgery
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
01
2023
accepted:
11
05
2023
medline:
28
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
This timely study assesses the immunosuppressive effects of surgery on cytotoxic Th1-like immunity and investigates if immune checkpoint blockade (ICB) can boost Th1-like immunity in the perioperative window in upper gastrointestinal cancer (UGI) patients. PBMCs were isolated from 11 UGI patients undergoing tumour resection on post-operative days (POD) 0, 1, 7 and 42 and expanded Th1-like immunity was suppressed in expanded PBMCs in the immediate post-operative setting. The frequency of expanded circulating Th1-like cells was significantly decreased post-operatively accompanied by a decrease in IFN-γ production and a concomitant increase in the frequency of expanded regulatory T cells with an increase in circulating levels of IL-10. Interestingly, PD-L1 and CTLA-4 immune checkpoint proteins were also upregulated on expanded Th1-like cells post-operatively. Additionally, the cytotoxic ability of expanded lymphocytes against oesophageal adenocarcinoma tumour cells was abrogated post-surgery. Of note, the addition of nivolumab or ipilimumab attenuated the surgery-mediated suppression of lymphocyte cytotoxicity, demonstrated by a significant increase in tumour cell killing and an increase in the frequency of Th1-like cells and Th1 cytokine production. These findings support the hypothesis of a surgery-mediated suppression in Th1-like cytotoxic immunity and highlights a rationale for the use of ICB within the perioperative setting to abrogate tumour-promoting effects of surgery and ameliorate the risk of recurrence.
Identifiants
pubmed: 37359545
doi: 10.3389/fimmu.2023.1150754
pmc: PMC10288841
doi:
Substances chimiques
Interleukin-10
130068-27-8
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Ipilimumab
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150754Informations de copyright
Copyright © 2023 Davern, Gaughan, O’ Connell, Moran, Mylod, Sheppard, Ramjit, Yun-Tong Kung, Phelan, Davey, Ryan, Butler, Quinn, Howard, Tone, Phoenix, Butt, Lynam-Lennon, Maher, Ravi, Donohoe, Reynolds, Lysaght and Donlon.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int Immunol. 2009 Oct;21(10):1105-11
pubmed: 19737784
J Thorac Dis. 2018 May;10(5):2691-2699
pubmed: 29997931
Br J Surg. 2000 Feb;87(2):236-42
pubmed: 10671934
Cell Metab. 2018 Jan 9;27(1):85-100.e8
pubmed: 29129787
Int J Mol Sci. 2018 Jul 09;19(7):
pubmed: 29987244
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Hepatobiliary Pancreat Dis Int. 2014 Oct;13(5):482-94
pubmed: 25308358
Cancer Lett. 2021 Apr 1;502:84-96
pubmed: 33450360
Front Immunol. 2020 Nov 11;11:587581
pubmed: 33262766
Clin Transl Med. 2020 Jan;10(1):199-223
pubmed: 32508035
Crit Rev Oncol Hematol. 2022 Jul;175:103729
pubmed: 35662586
J Immunother Cancer. 2018 Sep 3;6(1):86
pubmed: 30176921
Onco Targets Ther. 2019 Oct 15;12:8437-8445
pubmed: 31686860
Cancer Res. 2017 Apr 1;77(7):1548-1552
pubmed: 28330928
Expert Opin Biol Ther. 2021 Jun;21(6):697-703
pubmed: 33736560
Front Immunol. 2022 Jan 27;13:823225
pubmed: 35154142
Oncol Lett. 2012 Oct;4(4):625-630
pubmed: 23205074
Cancer Immunol Immunother. 2023 Jan;72(1):55-71
pubmed: 35708739